Table 2.

Relative reduction in LDL-C and non-HDL-C on background therapy of statins from network meta-analysis (random-effects)

	LDL-C* (95% credible interval)	Non-HDL-C* (95% credible interval)
Ezetimibe versus placebo	−17.8% (−23.7% to −11.9%)	−20.0% (−33.0% to −6.9%)
Inclisiran versus placebo	−51.3% (−61.9% to −40.5%)	−45.1% (−58.6% to −31.0%)
PCSK9 inhibitors versus placebo	−55.0% (−60.3% to −49.4%)	−47.0% (−54.3% to −39.4%)

*NMA of LDL-C included 19 RCTs, while NMA of non-HDL-C included 14 RCTs